A Shared Challenge
Alzheimer’s disease and related neurocognitive disorders are among the most urgent public health challenges of our time. With millions of people in Europe affected, and numbers projected to rise steeply in the coming decades, the need for early and accurate diagnosis has never been greater.
Biomarker-based approaches, particularly those involving nuclear medicine imaging, have the power to transform how we detect and manage these disorders. By identifying disease processes earlier and with more precision, clinicians can offer timely interventions, connect patients with emerging therapies and clinical trials, and provide families with clarity and support.
Why AD-LEARN
Despite progress, knowledge gaps persist:
Not all professionals are trained to use nuclear medicine methods in the diagnostic workflow.
Access and practices vary widely across European countries.
Inconsistent application of biomarkers leads to unequal patient care.
AD-LEARN was created to bridge these gaps.
Our mission is to:
Educate
deliver CME-accredited, high-quality training on biomarker-based diagnostics.
Unify
promote consistency across Europe in applying diagnostic workflows.
Empower
equip physicians, technologists, and researchers with the skills needed to improve patient care
Advance
strengthen the role of nuclear medicine in the multidisciplinary management of dementia.